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A B S T R A C T
Proliferative vitreoretinopathy (PVR) is a complication of rhegmatogenous retinal detachment and ocular
trauma. The disease is characterized by development of membranes that may apply traction to the retina and
cause redetachment. Membrane contractions are attributed to myofibroblasts arising from retinal pigment
epithelial cells, glia and fibroblasts. The progenitors of myofibrobasts in the lens are Myo/Nog cells that express
the skeletal muscle transcription factor MyoD and bone morphogenetic protein inhibitor Noggin. The retina and
choroid also contain Myo/Nog cells that respond to stress. We examined preretinal PVR membranes from three
ocular trauma patients with retinal detachment for Myo/Nog cells and their expression of muscle proteins. Myo/
Nog cells were identified by co-localization of antibodies to the G8 antigen and Noggin. Greater than 80% of all
cells in sections from two of three patients expressed both G8 and Noggin. Myo/Nog cells lacked pigment. Alpha
smooth muscle actin (α-SMA) and striated myosin II heavy chain were present in the majority of Myo/Nog cells
in these two patients. Differentiation of Myo/Nog cells was paralleled by low levels of MyoD. Membrane sections
from the third patient consisted mostly of connective tissue with very few cells. A small subpopulation in these
sections expressed both G8 and Noggin, and muscle proteins were detected in only a minority of G8-positive (+)
cells. In all three patients, greater than 99% of cells with MyoD, α-SMA and striated muscle myosin co-expressed
G8. These findings suggest that contractile myofibroblasts in PVR membranes may be derived from differ-
entiating Myo/Nog cells.
Proliferative vitreoretinopathy (PVR) is a vision threatening condi-
tion that occurs in 5–10% of patients following a rhegmatogenous
retinal detachment (Pastor, 1998; Pastor et al., 2002; Morescalchi et al.,
2013). The risk of developing PVR increases to up to 43% following
ocular trauma with perforation (Cardillo et al., 1997). The disease is
characterized by the formation of epi- and/or subretinal membranes
that may distort tissue architecture and cause redetachment (Pastor,
1998). The process of retinal membrane formation resembles a wound
healing response with proliferation of retinal pigment epithelial (RPE)
cells that undergo an epithelial-mesenchymal transition and become
migratory (Oberstein et al., 2011; Kroll et al., 2007; Heriot and
Machemer, 1992; Asaria and Charteris, 2006; Anderson et al., 1981;
Grisanti and Guidry, 1995; Casaroli-Marano et al., 1999; Baudouin
et al., 1990). Other components of these membranes are glial cells,
fibroblasts, myofibroblasts, leukocytes and extracellular matrix
(Baudouin et al., 1990; Garweg et al., 2013; Tosi et al., 2014). The
trigger for membrane formation is thought to be related to an injury-
induced compromise of endothelial tight junctions of the dual-layered
blood-retinal barrier and release of growth factors, mediators of che-
motaxis and inflammatory cytokines (Sadaka and Giuliari, 2012). Ret-
inal breaks and areas of detachment may result in leakage of fluid from
the vitreous into the subretinal space and the creation of conduits for
RPE migration onto the inner retinal surface (Morescalchi et al., 2013;
Cowley et al., 1989).
The most significant pathological feature of PVR membranes is their
ability to contract and produce traction on the retina (Glaser et al.,
1987). The likely mediators of membrane contractions are myofibro-
blasts. The proposed sources of myofibroblasts in retinal membranes
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are transdifferentiated RPE cells and fibroblasts (Pastor et al., 2002;
Oberstein et al., 2011; Kroll et al., 2007; Asaria and Charteris, 2006;
Glaser et al., 1987; Bochaton-Piallat et al., 2000).
In this study, preretinal membranes were examined for the presence
of an inherently myogenic cell type that we previously identified in the
retina and choroid (Bravo-Nuevo et al., 2016; Brandli et al., 2017).
These Myo/Nog cells were first discovered in the epiblast of the chick
embryo by their expression of mRNA for the skeletal muscle specific
transcription factor MyoD and bone morphogenetic protein inhibitor
Noggin (Gerhart et al., 2000, 2004, 2006). They are integrated into the
developing eye during early stages of development (Gerhart et al.,
2006, 2009). Depletion of Myo/Nog cells in the epiblast results in se-
vere malformations, including anophthalmia, microopathalmia, lens
dysgenesis and overgrowth of the retina (Gerhart et al., 2006, 2009,
2011).
Myo/Nog cells are also present in adult mammalian tissues (Bravo-
Nuevo et al., 2016; Brandli et al., 2017; Gerhart et al., 2012, 2014,
2018, 2019a, 2019b). In the lens, they are progenitors of contractile
myofibroblasts that deform the capsule (Gerhart et al., 2014, 2019a;
Walker et al., 2010). Targeted depletion of Myo/Nog cells during cat-
aract surgery in rabbits significantly reduces the emergence of myofi-
broblasts, capsular wrinkles and posterior capsule opacification
(Gerhart et al., 2019a).
The retina contains a low number of Myo/Nog cells under normal
conditions (Bravo-Nuevo et al., 2016; Brandli et al., 2017). Hypoxia and
light damage stimulate the proliferation and migration of Myo/Nog
cells to areas of stress and cell death (Bravo-Nuevo et al., 2016; Brandli
et al., 2017). Elimination of Myo/Nog cells in the mouse model of re-
tinopathy of prematurity results in increased neuronal cell death,
whereas their addition to the vitreous following light damage reduces
photoreceptor loss and improves visual function in rats (Bravo-Nuevo
et al., 2016; Brandli et al., 2017). While these studies indicate that
Myo/Nog cells are neuroprotective in the retina, their presence in the
ganglion cell layer, the interface between the inner nuclear and outer
plexiform layer, and choroid in the normal retina, along with their
potential to differentiate into myofibroblasts in the eye, led us to test
the hypothesis that Myo/Nog cells contribute to retinal membranes.
Preretinal membranes from three PVR patients that had suffered
retinal detachment from ocular trauma were screened for Myo/Nog cell
and muscle markers. Membranes were procured from patients in ac-
cordance with the Declaration of Helsinki and approved by the
Institutional Review Board of the University of California, Davis.
Informed consent was obtained before vitrectomy. Patients 1, 2 and 3
were males ages 34, 40 and 15, respectively. Six and eight weeks after
vitrectomy for retinal detachment, patients 1 and 2 again underwent
surgery for recurrent detachment with PVR. Patient 3 had a limited
retinal detachment from ocular trauma that was not repaired. His PVR
preretinal membrane was removed four years after injury to improve
vision. Surgical specimens were fixed immediately in 4% formalin,
embedded in paraffin and sectioned at 5 μM.
Tissue sections were stained with hematoxylin and eosin or double
labeled with the G8 mouse monoclonal antibody (mAb), a specific
marker for Myo/Nog cells (Gerhart et al., 2001, 2006, 2007, 2009,
2012, 2018, 2019a, 2019b), and an anti-Noggin goat polyclonal anti-
serum (AF719; R&D Systems, Minneapolis, MN), as described pre-
viously (Gerhart et al., 2001, 2006). Double labeling also was carried
out with G8 and either the anti-MyoD IgG1 mAb (MA5-12902, Ther-
moFisher Scientific, Rockford, IL) or anti-MyoD rabbit polyclonal an-
tiserum (ab203383, Abcam, Cambridge, MA), anti-α-SMA mAb (Sigma-
Aldrich, St. Louis, MO) and anti-striated muscle myosin II heavy chain
IgG 2b mAb (MF20 mAb; Developmental Studies Hybridoma Bank,
Iowa City, IO). The α-SMA mAb was directly conjugated with fluor-
escein. Other primary antibodies were tagged with AffiniPure Fab
fragment subclass and species-specific secondary antibodies conjugated
with Rhodamine Red or Alexa 488 (Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA). The level of background fluorescence was
assessed by labeling tissue sections with secondary antibodies only.
Tissues were analyzed with the Nikon Eclipse E800 epifluorescence
microscope (Nikon Instruments Inc., Melville, NY) equipped with 10x,
60x and 100x lenses, the Evolution QE Optronics video camera and
Image Pro Plus image analysis software program (Media Cybernetics,
Rockville MD). All cells were scored for the presence or absence of one
or both fluorescent antibodies in each section. The number of α-SMA
stained cells reported in Table 1 did not include smooth muscle sur-
rounding blood vessels. Photographs were adjusted for brightness and
contrast, and figures were annotated with Adobe Photoshop CC 2014
(Adobe Inc., San Jose, CA).
Tissue sections of preretinal membranes from the three patients
varied in size and appearance (Fig. 1A–C). Sections from patient 2
contained the largest amount of tissue. Membranes from patients 1 and
2 consisted of an abundance of cells and some collagenous extracellular
matrix. Sections from patient 3 contained few cells overall and was
mostly composed of fibrous connective tissue. The differences in the
cellularity and extent of fibrotic tissue in these sections reflects the age
of the membrane itself which had been present for four years in patient
3 versus six to eight weeks in patients 1 and 2. Pigment was visible in
very few cells in the membrane of patient 1 (Fig. 1 A). More pigmented
cells were present in patient 2's membrane but they were only a minor
population within the tissue (Fig. 1B). In patient 3's membrane, some
pigment appeared in fibrotic tissue lacking nuclei (Fig. 1C).
Sections of membranes from PVR patients 1 and 2 contained an
abundance of G8-positive (+) cells, whereas only a small subpopula-
tion bound the G8 mAb in patient 3 (Table 1). G8 and Noggin were
localized to the same cells in all three patients (Table 1; Fig. 1D–F).
Noggin + cells lacking detectable levels of G8 were extremely rare (less
than 0.1%) in patient 3 (Table 1). Low numbers of G8+ cells in patients
1–3 contained detectable levels of MyoD protein (Table 1). All cells
with MyoD cells were co-labeled with the G8 mAb except for tissue
from patient 1 in which only a few MyoD+/G8-cells were observed
(Table 1; Fig. 1G–I).
PVR membrane sections also were screened for muscle filament
proteins. Levels of α-SMA were high in patients 1 and 2, and very low in
patient 3 (Table 1; Fig. 1J-L). The majority of G8+ Myo/Nog cells had
Table 1
Quantitation of cells expressing Myo/Nog cell markers and muscle pro-
teins in PVR membranes. Tissue sections were double labeled with antibodies
to G8 and Noggin, α-SMA or striated muscle myosin. Percent posi-
tive = number of fluorescent cells ÷ total number of cells X 100. Percentage of
G8+ cells labeled with another primary antibody = number of double labeled
cells ÷ total number of G8+ cells X 100. Percentage of Noggin+, MyoD+, α-
SMA + or myosin + cells labeled with G8 = number of double labeled
cells ÷ total number of fluorescent cells X 100. α-SMA stained cells sur-
rounding blood vessels were not counted. Results are the mean ± standard
deviation. The number of sections scored is indicated in parenthesis.
Percent Positive Patient 1 Patient 2 Patient 3
G8+ 87 ± 7 (12) 88 ± 6 (12) 11 ± 3 (12)
Noggin+ 79 ± 8 (3) 88 ± 5 (3) 12 ± 4 (3)
G8+ with Noggin 100 (3) 100 (3) 100 (3)
Noggin+ with G8 100 (3) 100 (3) 99.9 ± 0.05 (3)
MyoD+ 4 ± 1 (3) 0.3 ± 0.1 (3) 6 ± 2 (3)
G8+ with MyoD 5 ± 1 (3) 0.3 ± 0.1 (3) 47 ± 23 (3)
MyoD+ with G8 99.9 ± 0.05 (3) 100 (3) 100 (3)
α-SMA+ 66 ± 10 (3) 72 ± 6 (3) 3 ± 3 (3)
G8+ with α-SMA 74 ± 7 (3) 80 ± 3 (3) 42 ± 41 (3)
α-SMA with G8 100 (3) 99 ± 1 (3) 100 (3)
Myosin+ 58 ± 3 (3) 64 ± 15 (3) 1 ± 1 (3)
G8+ with Myosin 63 ± 4 (3) 75 ± 11 (3) 16 ± 14 (3)
Myosin + with G8 100 (3) 100 (3) 100 (3)
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synthesized α-SMA in the first two patients. Less than 20% of G8+ cells
were stained for α-SMA in two out of three sections from Patient 3
(Fig. 1L). A single cluster of double labeled cells was present in the third
section. All α-SMA + cells contained G8 with the exception of patient 2
in which α-SMA+/G8-negative (−) cells were rare (< 1%) (Table 1;
Fig. 1J-L).
Similar results were obtained for the expression of striated muscle
myosin. The majority of G8+ cells were labeled with the myosin mAb
in patients 1 and 2, whereas only a small number of Myo/Nog cells in
patient 3 were myosin+ (Table 1). All cells with myosin were labeled
with the G8 mAb in all three patients (Table 1; Fig. 1M–O). Some G8+
cells appeared to be multinucleated in membrane sections from patient
1 (Fig. 1G).
The results of this study demonstrate that Myo/Nog cells are present
in trauma-induced preretinal membranes from PVR patients and the
cells are in different states of maturation. The majority of G8+ cells in
Fig. 1. Co-expression of Myo/Nog and muscle proteins in PVR membranes. Tissue sections of preretinal membranes from patients 1–3 were stained with H&E or
double labeled with the G8 mAb (red) and antibodies to Noggin (Nog), MyoD, α-SMA or striated muscle myosin (green). The overlap of red and green appears yellow
in merged images. Single labeled cells are indicated with white arrows. Green arrows in G indicate cells that appear multinucleated. Areas with pigment are shown in
the insets in A-C. Bar = 54 μM in A-C and 9 μMin D-O. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of
this article.)
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the two patients with recently formed membranes had undergone dif-
ferentiation, as evidenced by their expression of α-SMA and striated
muscle myosin, and low levels of MyoD that is downregulated with
skeletal muscle maturation (Hinterberger et al., 1991). The number of
Myo/Nog cells was low in the third patient whose membrane contained
few cells overall. In this patient's tissue sections, the majority of G8+
cells were not labeled with antibodies to MyoD, α-SMA and striated
muscle myosin. This suggests that most G8+/Noggin + cells in patient
3 were quiescent progenitors because MyoD mRNA translation is not
detected until Myo/Nog cells are activated (Gerhart et al., 2001, 2012,
2014, 2019a; George-Weinstein et al., 1996; Strony et al., 2005).
This study introduces a previously undescribed cell type into the
PVR disease process. While the origin of Myo/Nog cells in preretinal
membranes is unknown, the retinal ganglion cell layer, interface of the
inner nuclear and plexiform layer, and choroid normally contain Myo/
Nog cells (Bravo-Nuevo et al., 2016; Brandli et al., 2017). An additional
potential source of Myo/Nog cells is the ciliary body (Gerhart et al.,
2018, 2019a). In the retina, ciliary body and lens, Myo/Nog cells in-
crease in number and migrate in response to stress and injury (Bravo-
Nuevo et al., 2016; Brandli et al., 2017; Gerhart et al., 2018, 2019a).
These properties, along with their stable commitment to the skeletal
muscle lineage regardless of their environment (Gerhart et al., 2007)
and tendency to differentiate into myofibroblasts that express striated
muscle proteins after injury to the lens (Gerhart et al., 2014, 2017,
2019a; Walker et al., 2010), suggest that Myo/Nog cells contribute to
retinal membrane formation and contractions.
Myo/Nog cells do not express markers of the monocyte/macrophage
lineage in the retina and elsewhere (Bravo-Nuevo et al., 2016; Brandli
et al., 2017; Gerhart et al., 2012), and therefore, it is unlikely that
microglia transdifferentiated into myofibroblasts expressing G8 and
Noggin. Fibroblasts and fibroblast-like cells also have been implicated
as a source of myofibroblasts in retinal membranes (Grisanti and
Guidry, 1995; Baudouin et al., 1990); however, they are morphologi-
cally similar to Myo/Nog cells. Our study cannot rule out the possibility
that RPE cells transdifferentiated into Myo/Nog cells and myofibro-
blasts. While RPE cells are capable of expressing α-SMA in vitro
(Kurosaka et al., 1996; Stocks et al., 2001; Ando et al., 2000; Si et al.,
2013), to our knowledge they have not been screened for expression of
striated muscle proteins. Furthermore, Myo/Nog cell markers were not
detected in RPE cells in vivo even under conditions of stress (Bravo-
Nuevo et al., 2016; Brandli et al., 2017). Pigment was not observed in
G8+ cells within the retina (Bravo-Nuevo et al., 2016; Brandli et al.,
2017) or PVR membranes, although loss of pigment accompanies the
epithelial to mesenchymal transition of RPE cells (Campochiaro et al.,
1991; Lee et al., 2001). Screening of RPE cells for markers of Myo/Nog
cells and striated muscle proteins in vitro and models for inducing PVR
in vivo may reveal whether there is a lineage relationship between the
two cell types. In this context, it is important to note that once Myo/
Nog cells are depleted in the chick embryo and human lens tissue, they
are not replaced by stem or transdifferentiating cells (Gerhart et al.,
2006, 2009, 2011, 2014, 2017, 2019a; Sadaka and Giuliari, 2012;
Telander et al., 2011).
Regardless of the origin of Myo/Nog cells in retinal membranes,
targeting them for elimination during surgical repair of a detached
retina is worthy of consideration.
While the anatomic success rate of surgery is estimated at 60–80%
for redetachments caused by PVR, only 40–80% of patients experience
functional success with an ambulatory vision of 5/200 or greater
(Sadaka and Giuliari, 2012). Current adjunct pharmacological ap-
proaches to prevent PVR include administration of drugs and biologics
that inhibit inflammation, proliferation, oxidation, epithelial to me-
senchymal transition, adhesion, remodeling of the extracellular matrix
and cell migration (Morescalchi et al., 2013; Sadaka and Giuliari,
2012). These approaches are effective in reducing PVR in animal
models (Sadaka and Giuliari, 2012; Telander et al., 2011), but thus far,
limited success has been achieved with those drugs that have been
tested in clinical trials (Morescalchi et al., 2013; Sadaka and Giuliari,
2012).
Myo/Nog cells have been killed in explants of human lens tissue and
in the rabbit lens during cataract surgery using a drug consisting of the
targeting G8 mAb conjugated to 3DNA intercalated with the cytotoxin
doxorubicin (Gerhart et al., 2017, 2019a). In both studies, off-target
effects of the drug were not observed and treatment prevented the
emergence of myofibroblasts and contractions. Injection of a drug that
specifically targets Myo/Nog cells in animal models of PVR will help
resolve questions surrounding the origin of contractile cells in retinal
membranes and simultaneously test this approach for disease modifying
effects.
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